Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

es C Stock and the Series D Stock of $0.7 million.

The Company reported a net loss applicable to common stock for the third quarter of 2010 of $3.1 million, or $0.11 per basic and diluted share, which includes charges of $0.8 million, or $0.03 per basic and diluted share, related to preferred stock dividends in connection with the Company's Series C Stock and Series D Stock.  For the same period in 2009, the Company reported a net loss applicable to common stock of $4.2 million, or $0.15 per basic and diluted share, which included charges related to preferred stock dividends in connection with the Series C Stock and the Series D Stock of $0.8 million, or $0.03 per basic and diluted share.

For the nine months ended September 30, 2010, the Company reported a net loss of $10.3 million, as compared with a net loss of $10.6 million for the nine months ended September 30, 2009.  Net loss includes charges for the change in estimated fair value of derivative financial instruments related to warrants previously issued in connection with the issuance of the Series C Stock and the Series D Stock of $2.9 million and $2.7 million for the first nine months of 2010 and 2009, respectively.  The Company reported a net loss applicable to common stock for the nine months ended September 30, 2010, of $12.6 million, or $0.45 per basic and diluted share, which includes charges of $2.4 million, or $0.09 per basic and diluted share, related to preferred stock dividends in connection with the Series C Stock and the Series D Stock.  For the nine months ended September 30, 2009, the Company reported a net loss applicable to common stock of $12.8 million, or $0.46 per basic and diluted share, which included charges of $2.2 million, or $0.08 per basic and diluted share, related to preferred stock dividends in connection with the Series C Stock and the Series D Stock.

Neurologix had cash and cash equivalents of $3 million at September 30, 2010.

The
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 The consumer marketing playbook and ... sectors to better identify winning tools and techniques. ... with and understand consumers, as new technologies are ... purchasing decisions. According to recent ... area where organizations can observe a deep pool ...
(Date:7/11/2014)... , July 11, 2014 ... Market by Composition of Material, Application (Healthcare, Homeland ... End Product (Personal Instrument, Hand-Held Instruments, Fixed, and ... Analysis to 2013 - 2020", published by MarketsandMarkets, the Scintillator ... of 5.62% from 2014 to 2020, and reach ...
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3
... HUNTSVILLE, Ala., Nov. 15, 2011 Bayer Technology ... new Bayer MaterialScience production site at Caojing in ... solutions. The new process technology significantly reduces solvent ... and carbon dioxide emissions. (Logo: http://photos.prnewswire.com/prnh/20081211/DECLOGO) ...
... Shurtleff, Inc. (Codman), a global neuroscience and neurovascular company, ... Valve, a shunt used in the treatment of congenital ... (CSF) in the brain.  Over the ... treat approximately 150,000 patients suffering from hydrocephalus in the ...
Cached Medicine Technology:Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China 2Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China 3Codman Launches CERTAS™ Programmable Valve for Hydrocephalus 2Codman Launches CERTAS™ Programmable Valve for Hydrocephalus 3Codman Launches CERTAS™ Programmable Valve for Hydrocephalus 4
(Date:7/13/2014)... A Xarelto lawsuit webpage has been launched ... with the most current information regarding serious internal bleeding ... as well as the growing number of Xarelto ... The law firm is now offering free legal evaluations ... bleeding and related complications while using Xarelto, including:, ...
(Date:7/13/2014)... 2014 According to The Peripheral Neuropathy ... comprehensive program that teaches people how to deal with ... without medications. This program also provides people with safe ... neuropathy , including numbness, prickling, burning, and intense stabbing ... this home treatment program can help people eliminate some ...
(Date:7/12/2014)... 2014 Recently, iFitDress.com, one of the world’s ... red evening gowns . What’s more, all these hot ... , The company’s senior spokesman states, “We are proud to ... website is an enjoyable shopping experience. In addition to the ... store, low prices do not always mean bad quality. All ...
(Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
(Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... Stiefel Laboratories, Inc.,("Stiefel Laboratories"), the world,s ... today that the waiting,period under the Hart-Scott-Rodino ... Act") has expired, for its proposed acquisition ... BTRX )., As previously announced, Stiefel ...
... of Adelaide have developed a novel approach to treating ... fewer side effects. , Professor Wayne Tilley and Dr ... Research Laboratories have discovered that by using existing prostate ... doses, they can expect to generate better results for ...
... smoking spouse quits , , TUESDAY, July 29 (HealthDay News) -- ... risk for experiencing a stroke, a new study suggests. , ... who still smoke carry an even greater risk for stroke. ... bear any higher risk for stroke than those married to ...
... Southern Home Medical,Equipment, Inc. (OTC: SHOM) announced today ... solid growth. Industry statistics,suggest a very favorable market ... from the U.S. Bureau of Labor Statistics published ... one million new and,replacement nurses will be needed ...
... for Excellence Issue Brief, WASHINGTON, July 29 ... has issued its second issue brief on retiree,health ... Estimates,of Liabilities. The brief, which was written by ... and entrepreneurship in the,College of Management, North Carolina ...
... single women identify any gaps in coverage or inadequate protection ... ... 2008 -- http://www.combinedinsurance.com/ [Combined Insurance], a leading provider ... 27-August 2, 2008, sponsored by SWWAN® (Single Working Women,s Affiliate ...
Cached Medicine News:Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 2Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 3Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 4Health News:New treatment for advanced prostate cancer 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3Health News:Southern Home Medical's Encore Medical Staffing Division Poised to Benefit from Major Growth in Nursing Industry 2Health News:Financing Retiree Health Care: Assessing GASB 45 Estimates of Liabilities 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 3Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 4Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 5
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: